Indian Journal of Medical and Paediatric Oncology, Table of Contents CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(02): 180-181DOI: 10.1055/s-0041-1730090 Report on International Publication Identifying Myeloma Patients at Risk of Lenalidomide or Pomalidomide Resistance at Relapse: A New Opportunity Authors Author Affiliations Suvir Singh 1 Department of Clinical Hematology and Stem Cell Transplantation, Dayanand Medical College, Ludhiana, Punjab, India Recommend Article Abstract Full Text References References 1 Gooding S, Ansari-Pour N, Towfic F. et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood 2021; 137 (02) 232-237 2 Krönke J, Udeshi ND, Narla A. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014; 343 (61/68) 301-305 3 Klimowicz A, Neri P, Belch A. et al. High cereblon protein expression correlates with improved response and survival in myeloma patients treated with lenalidomide. American Society of Hematology Blood 2012; 120 (21) 931 4 Schuster SR, Kortuem KM, Zhu YX. et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res 2014; 38 (01) 23-28 5 Franssen LE, Nijhof IS, Couto S. et al. Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. Haematologica 2018; 103 (08) e368-e371 6 Dimopoulos K, Fibiger Munch-Petersen H, Winther Eskelund C. et al. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. Leuk Lymphoma 2019; 60 (01) 180-188 7 Thakurta A, Gandhi AK, Waldman MF. et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia 2014; 28 (05) 1129-1131 8 Lodé L, Amiot M, Maiga S. et al. Cereblon expression in multiple myeloma: not ready for prime time. Br J Haematol 2013; 163 (02) 282-284 9 Qian X, Dimopoulos MA, Amatangelo M. et al. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. Leuk Lymphoma 2019; 60 (02) 462-470 10 Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J 2020; 10 (09) 94 11 Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood 2019; 133 (07) 660-675
